台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

(ME3-3) 攝護腺切除術後尿失禁(PPI)的診斷與治療_林志杰

2022-09-28 • 觀看: 14 • 回應: 0 • 影片
(LS5-2) Case discussion: ICI for adjuvant MIUC_王紹全

2022-09-28 • 觀看: 25 • 回應: 0 • 影片
(LS5-1) Emerging role of adjuvant immune checkpoint inhibitor in muscle-invasive urothelial cancer_葉士芃

2022-09-28 • 觀看: 16 • 回應: 0 • 影片
(ME1-3) Technical tips for robotic intracorporeal urinary diversion in robotic radical cystectomy_虞凱傑

2022-09-28 • 觀看: 17 • 回應: 0 • 影片
(ME1-1) Challenging situations in robot-assisted partial nephrectomy_呂育全

2022-09-28 • 觀看: 14 • 回應: 0 • 影片
(IS5-1) Complications of PCNL : Risk factors and management PCNL的風險防控_石宏仁

2022-09-28 • 觀看: 31 • 回應: 0 • 影片
(IS4-2) Pathophysiology of IC/BPS and potential urinary biomarkers for diagnosis_阮雍順

2022-09-28 • 觀看: 22 • 回應: 0 • 影片
(IS4-1) Current classification and differential diagnosis of interstitial cystitis/ bladder pain syndrome – based on clinical symptoms, urodynamic tests, and histological study_蒙恩

2022-09-28 • 觀看: 30 • 回應: 0 • 影片
(IS4-3) Novel treatments of different subtypes of interstitial cystitis/ bladder pain syndrome – medical, intravesical treatment, surgery_張嘉峰

2022-09-28 • 觀看: 15 • 回應: 0 • 影片
(IS3-2) Risk of metabolic and cardiovascular adverse events with NHA among men with advanced prostate cancer_陳毓騏

2022-09-28 • 觀看: 19 • 回應: 0 • 影片
(IS3-1) Real-world evidence of using NHA in Taiwanese prostate cancer patients_陳忠信

2022-09-28 • 觀看: 28 • 回應: 0 • 影片
(LS4-1) Myths about bone-targeted therapy: Optimal strategy for incorporating BTAs into treatment paradigms for PCa_洪健華

2022-09-28 • 觀看: 27 • 回應: 0 • 影片

Prev
537
538
539
540
541
542
543
544
545
546
Next
/ 1264